New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
06:39 EDTCLVS, AZNClovis downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Clovis Oncology(CLVS) to Neutral saying AstraZeneca's AZD9291 looks comparatively better than the company's CO-1686. Citi cut its price target for Clovis shares to $53 from $109.
News For CLVS;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
06:55 EDTAZNAstraZeneca announces four research collaborations for CRISPR
Subscribe for More Information
January 28, 2015
07:39 EDTAZNPfizer CEO says company not in need of big M&A deal, FT reports
Subscribe for More Information
January 27, 2015
12:54 EDTAZNBox, Inc. lands AstraZeneca contract to service 51,000 users, Re/code reports
Subscribe for More Information
January 26, 2015
15:24 EDTAZNTeva confirms U.S. approval of AstraZeneca's Nexium generic
Subscribe for More Information
13:10 EDTCLVSOppenheimer reports 5.23% passive stake in Clovis
January 21, 2015
12:30 EDTAZNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:16 EDTAZNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use